Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Biomarkers to Guide Diagnosis, Treatment of Rheumatic Diseases

Rick Brasington, MD  |  Issue: January 2015  |  

Looking Ahead

Although we do not yet have idea biomarkers for RA, progress has been made. We can hope that over the next few years, we will have even better biomarkers to guide our diagnosis and treatment.

Rick Brasington, MD, is a rheumatologist and fellowship program director at Washington University in St. Louis, and an associate editor of The Rheumatologist.

ADVERTISEMENT
SCROLL TO CONTINUE

Related Articles

    More Evidence Biomarkers Predict RA Relapse with DMARD Taper

    NEW YORK (Reuters Health)—For rheumatoid arthritis (RA) patients in stable remission, a panel of inflammatory markers in blood can help predict the odds of relapse when disease-modifying anti-rheumatic drug (DMARD) therapy is tapered, say researchers from Germany. The multibiomarker disease activity (MBDA) score, when combined with anticitrullinated protein antibody (ACPA) testing, can predict relapse in…

    Progress Slow in Development of Useful Biomarkers for Rheumatoid Arthritis Treatment

    LONDON—Josef Smolen, MD, chair of rheumatology at the University of Vienna and former president of the European League Against Rheumatism (EULAR), expressed a “personal disappointment” in the development of useful biomarkers in the treatment of rheumatoid arthritis (RA). Even though a good portion of his life’s work has been researching biomarkers to help with targeting…